바로가기메뉴

본문 바로가기 주메뉴 바로가기

Efficacy and Safety of Gabapentin in the Treatment of Chronic Cough: A Systematic Review

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2018, v.81 no.3, pp.167-174
Guanglin Shi (Nantong Pulmonary Hospital)
Qin Shen (Medical School of Nantong University)
Caixin Zhang (Medical School of Nantong University)
Jun Ma (Medical School of Nantong University)
Anaz Mohammed (Medical School of Nantong University)
Huan Zhao (Nantong Pulmonary Hospital)
  • Downloaded
  • Viewed

Abstract

Despite recent clinical guidelines, the optimal therapeutic strategy for the management of refractory chronic cough is still a challenge. The present systematic review was designed to assess the evidence for efficacy and safety of gabapentin in the treatment of chronic cough. A systematic search of PubMed, Embase, Cochrane Library databases, and publications cited in bibliographies was performed. Articles were searched by two reviewers with a priori criteria for study selection. Seven relevant articles were identified, including two randomized controlled trials, one prospective case-series designed with consecutive patients, one retrospective case series of consecutive patients, one retrospective case series with unknown consecutive status, and two case reports comprising six and two patients, respectively. Improvements were detected in cough-specific quality of life (Leicester Cough Questionnaire score) and cough severity (visual analogue scale score) following gabapentin treatment in randomized controlled trials. The results of prospective case-series showed that the rate of overall improvement of cough and sensory neuropathy with gabapentin was 68%. Gabapentin treatment of patients with chronic cough showed superior efficacy and a good safety record compared with placebo or standard medications. Additional randomized and controlled trials are needed.

keywords
Gabapentin, Cough, Treatment, Review Literature as Topic, Safety

Reference

1.

Gibson PG, Ryan NM. Cough pharmacotherapy: current and future status. Expert Opin Pharmacother 2011;12:1745-55.

2.

Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003;58:339-43.

3.

Chung KF, Pavord ID. Prevalence, pathogenesis, and causes of chronic cough. Lancet 2008;371:1364-74.

4.

Birring SS. Controversies in the evaluation and management of chronic cough. Am J Respir Crit Care Med 2011;183:708- 15.

5.

Pratter MR. Unexplained (idiopathic) cough: ACCP evidence-based clinical practice guidelines. Chest 2006;129(1 Suppl):220S-1S.

6.

Ryan NM, Gibson PG, Birring SS. Arnold's nerve cough reflex: evidence for chronic cough as a sensory vagal neuropathy. J Thorac Dis 2014;6(Suppl 7):S748-52.

7.

Canning BJ, Chang AB, Bolser DC, Smith JA, Mazzone SB, McGarvey L, et al. Anatomy and neurophysiology of cough: CHEST Guideline and Expert Panel report. Chest 2014;146: 1633-48.

8.

Haque RA, Usmani OS, Barnes PJ. Chronic idiopathic cough: a discrete clinical entity? Chest 2005;127:1710-3.

9.

Chung KF. Chronic ‘cough hypersensitivity syndrome’: a more precise label for chronic cough. Pulm Pharmacol Ther 2011;24:267-71.

10.

Bastian RW, Vaidya AM, Delsupehe KG. Sensory neuropathic cough: a common and treatable cause of chronic cough. Otolaryngol Head Neck Surg 2006;135:17-21.

11.

Chung KF, McGarvey L, Mazzone SB. Chronic cough as a neuropathic disorder. Lancet Respir Med 2013;1:414-22.

12.

Cohen SM, Misono S. Use of specific neuromodulators in the treatment of chronic, idiopathic cough: a systematic review. Otolaryngol Head Neck Surg 2013;148:374-82.

13.

Cukier-Blaj S, Bewley A, Aviv JE, Murry T. Paradoxical vocal fold motion: a sensory-motor laryngeal disorder. Laryngoscope 2008;118:367-70.

14.

Lee B, Woo P. Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment. Ann Otol Rhinol Laryngol 2005;114:253-7.

15.

Mintz S, Lee JK. Gabapentin in the treatment of intractable idiopathic chronic cough: case reports. Am J Med 2006;119:e13- 5.

16.

Murry T, Branski RC, Yu K, Cukier-Blaj S, Duflo S, Aviv JE. Laryngeal sensory deficits in patients with chronic cough and paradoxical vocal fold movement disorder. Laryngoscope 2010;120:1576-81.

17.

Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet 2012;380:1583-9.

18.

Vertigan AE, Gibson PG. Chronic refractory cough as a sensory neuropathy: evidence from a reinterpretation of cough triggers. J Voice 2011;25:596-601.

19.

Fan H, Yu W, Zhang Q, Cao H, Li J, Wang J, et al. Efficacy and safety of gabapentin 1800 mg treatment for post-herpetic neuralgia: a meta-analysis of randomized controlled trials. J Clin Pharm Ther 2014;39:334-42.

20.

Kimos P, Biggs C, Mah J, Heo G, Rashiq S, Thie NM, et al. Analgesic action of gabapentin on chronic pain in the masticatory muscles: a randomized controlled trial. Pain 2007;127:151-60.

21.

Madanick R, Sigmon L, Ferrell K, Shaheen N, Dellon E. Gabapentin for the treatment of chronic cough: a novel approach to treating a challenging clinical problem. Am J Gastroenterol 2012;107 Suppl 1:S27-8.

22.

Ting L, Na C. The efficiency and safety of gabapentin in the treatment of pertinacious chronic cough. Int Med Health Guid News 2016;22:665-8.

23.

Van de Kerkhove C, Goeminne PC, Van Bleyenbergh P, Du- pont LJ. A cohort description and analysis of the effect of gabapentin on idiopathic cough. Cough 2012;8:9.

24.

Bastian ZJ, Bastian RW. The use of neuralgia medications to treat sensory neuropathic cough: our experience in a retrospective cohort of thirty-two patients. PeerJ 2015;3:e816.

25.

Fischer JH, Barr AN, Rogers SL, Fischer PA, Trudeau VL. Lack of serious toxicity following gabapentin overdose. Neurology 1994;44:982-3.

26.

Verma A, St Clair EW, Radtke RA. A case of sustained massive gabapentin overdose without serious side effects. Ther Drug Monit 1999;21:615-7.

Tuberculosis & Respiratory Diseases